Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Shares Outstanding (Diluted Average) (2016 - 2025)

IGC Pharma (IGC) has disclosed Shares Outstanding (Diluted Average) for 11 consecutive years, with $86.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 16.59% to $86.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $86.8 million, a 16.59% increase, with the full-year FY2025 number at $76.5 million, up 30.04% from a year prior.
  • Shares Outstanding (Diluted Average) was $86.8 million for Q3 2025 at IGC Pharma, up from $83.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $86.8 million in Q3 2025 to a low of $53.7 million in Q3 2023.
  • A 3-year average of $71.2 million and a median of $74.4 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 38.59% in 2024, then grew 14.03% in 2025.
  • IGC Pharma's Shares Outstanding (Diluted Average) stood at $57.0 million in 2023, then soared by 36.11% to $77.6 million in 2024, then increased by 11.76% to $86.8 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Shares Outstanding (Diluted Average) are $86.8 million (Q3 2025), $83.0 million (Q2 2025), and $76.5 million (Q1 2025).